Transcriptomics Technologies

Global Transcriptomics Technologies Market to Reach US$12.0 Billion by 2030

The global market for Transcriptomics Technologies estimated at US$7.9 Billion in the year 2024, is expected to reach US$12.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 7.1% CAGR

The Transcriptomics Technologies market in the U.S. is estimated at US$2.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global "Transcriptomics Technologies" Market - Key Trends & Drivers Summarized

Why Is Transcriptomics Taking Center Stage in the Era of Precision Medicine?

Transcriptomics—the comprehensive study of RNA transcripts produced by the genome—has rapidly evolved into a cornerstone of modern biomedical research, especially within the expanding domain of precision medicine. By analyzing the dynamic expression of genes in different tissues, cell types, and disease states, transcriptomics offers unparalleled insights into cellular function and pathology. This capability has transformed how scientists diagnose diseases, identify biomarkers, and stratify patients for targeted therapies. The COVID-19 pandemic notably accelerated global awareness of omics technologies, including transcriptomics, as researchers used RNA profiling to track viral evolution and host responses. In oncology, transcriptome sequencing is now frequently used to understand tumor heterogeneity and identify novel drug targets. Additionally, rare disease research has seen breakthroughs through transcriptomic analysis, allowing for better classification and understanding of monogenic disorders. As biopharma companies deepen their investment in personalized therapeutics, the role of transcriptomics in drug discovery, toxicogenomics, and clinical trial optimization has expanded dramatically. This growing clinical and commercial relevance underscores why transcriptomics technologies are now regarded not just as research tools but as foundational to the next generation of diagnostics and therapeutics.

How Are Next-Gen Sequencing and Bioinformatics Powering Transcriptomics Innovation?

The explosive growth of transcriptomics owes much to technological breakthroughs in next-generation sequencing (NGS), single-cell RNA sequencing (scRNA-seq), and high-throughput microarray platforms. These tools enable researchers to capture gene expression data at unprecedented resolution and scale, revealing both broad trends and subtle variations in gene activity. Single-cell techniques, in particular, are revolutionizing the field by mapping transcriptomes at the level of individual cells, uncovering previously hidden cell subtypes and disease mechanisms. Meanwhile, advancements in long-read sequencing technologies are addressing limitations in transcript isoform detection and alternative splicing analysis. However, the deluge of data generated from transcriptomics studies requires sophisticated computational tools to manage, interpret, and visualize results. AI and machine learning models are increasingly applied to identify complex patterns, predict gene function, and automate the classification of cell types. Cloud-based bioinformatics platforms and open-source databases have made these powerful tools more accessible to researchers around the world. This integration of wet-lab innovation with dry-lab analytics is not only expanding the utility of transcriptomics but also accelerating the time-to-discovery across multiple therapeutic areas.

Can Transcriptomics Technologies Bridge the Gap Between Genomics and Functional Biology?

While genomics reveals the blueprint of life, transcriptomics provides real-time snapshots of how that blueprint is interpreted under varying biological and environmental conditions. This distinction has made transcriptomics essential for functional genomics and systems biology, where understanding gene activity in context is critical. In immunology, for example, transcriptomic profiling is being used to monitor immune cell activation and identify cytokine signatures associated with autoimmune diseases or vaccine responses. Neuroscience research is increasingly reliant on spatial transcriptomics—an emerging method that maps gene expression within tissue architecture—to explore brain cell diversity and neurodegenerative disease pathways. Environmental transcriptomics is another fast-emerging application, helping ecologists assess stress responses in plants and animals to climate change and pollution. Agricultural genomics also benefits from transcriptomics, enabling the breeding of crops with improved yield, stress tolerance, and resistance to pests. These cross-sector applications reflect a growing consensus that transcriptomics bridges the critical gap between static genomic data and dynamic cellular function, making it indispensable not just in healthcare, but across the broader life sciences ecosystem.

The Growth in the Transcriptomics Technologies Market Is Driven by Several Factors…

The growth in the transcriptomics technologies market is driven by several factors linked to research demand, technological maturity, and end-user expansion. A key catalyst is the rise of personalized medicine, where RNA profiling plays a central role in identifying patient-specific disease pathways and tailoring treatments. Increased funding for life sciences research—by both governments and private investors—is supporting large-scale transcriptomics studies in areas like oncology, infectious disease, and neurobiology. Technological advancements such as single-cell sequencing, spatial transcriptomics, and high-throughput automation are enabling broader, more detailed transcriptomic analyses at lower costs. Pharmaceutical companies are incorporating transcriptomics into drug development pipelines to de-risk compounds, understand off-target effects, and accelerate regulatory approval processes. Clinical laboratories are beginning to adopt transcriptomic panels as diagnostic tools, particularly in oncology and rare disease testing. Furthermore, the proliferation of bioinformatics platforms and user-friendly data visualization tools has democratized transcriptomics, empowering researchers in academia and industry alike. Regulatory frameworks are gradually adapting to accommodate transcriptomics-based diagnostics, opening new pathways for commercialization. Collectively, these drivers are transforming transcriptomics from a niche scientific method into a vital engine of biomedical and life science innovation.

SCOPE OF STUDY:

The report analyzes the Transcriptomics Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Consumables, Instruments, Software, Services); Technology (Microarrays, qPCR, Sequencing Technology); Application (Drug Discovery, Diagnostics & Disease Profiling, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

• 10x Genomics
• Agilent Technologies Inc.
• Becton, Dickinson and Company (BD)
• Bio-Rad Laboratories, Inc.
• BGI Genomics
• Danaher Corporation
• Fluidigm Corporation
• F. Hoffmann-La Roche Ltd
• GE Healthcare
• Illumina, Inc.
• LC Sciences, LLC
• Merck KGaA
• NanoString Technologies, Inc.
• PerkinElmer Inc.
• Promega Corporation
• Qiagen N.V.
• Revvity, Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Vizgen, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.